Mannkind Cp: (NASD: MNKD)

$7.02

0.42 (6.28%)

Volume 11,076,972

Jun 19 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		6.65 - 7.25
	
		52wk Low - High
		1.79 - 8.06
	
		Previous Close
		6.61
	
		Avg. Volume
		11,511,901
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		1.92 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.32
	
		P/E (F1)
		0.00
	
		Current Year Est.
		-0.49
	
		Quarterly Earnings ESP 
		NA
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		112 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/14/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -0.49
                        
                            Current Quarter Estimate
                            -0.15
                        
                            Most Accurate Estimate
                            NA
                        
                            Earnings ESP 
                            NA
                        
                            Next Earnings Report Date
                            08-06-2013
                        
                            EPS Last Year
                            -0.83
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung.   
Full MNKD Company Report

 Analyst Report on MNKD

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
MNKD Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.15	-0.13	-0.49	-0.21
Number of Estimates	4	3	5	4
Low Estimate	-0.17	-0.15	-0.54	-0.37
High Estimate	-0.13	-0.12	-0.39	NA
Year Ago EPS	-0.23	-0.22	-0.94	-0.49
EPS Growth	36.96%	39.39%	47.45%	56.98%

More MNKD Estimates

Average Earnings Estimates for MNKD

EPS Growth for MNKD

Industry Analysis

Name	Symbol	Previous Close
MANNKIND CORP	MNKD	6.61
AETERNA ZENTARS	AEZS	1.90
BIOGEN IDEC INC	BIIB	210.80
MYRIAD GENETICS	MYGN	26.44
PROTALIX BIOTHR	PLX	5.08
ADDEX THERA LTD	ADDXF	3.95
AFFYMAX INC	AFFY	1.07
ALEXION PHARMA	ALXN	92.39
ALNYLAM PHARMA	ALNY	29.99
ANTHERA PHARMA	ANTH	0.58

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

MannKind Completes Afrezza Studies

Jun 18, 2013

MannKind Progresses on Afrezza

Jun 03, 2013

Narrower-than-Expected Loss at MannKind

May 13, 2013

Loss at MannKind Wider than Expected

Feb 12, 2013

MannKind Inks Deal with Colby

Nov 15, 2012

MannKind Cuts 3Q Loss

Nov 02, 2012

Mann Group to Buy MNKD's Shares

Oct 23, 2012

MannKind to Raise Funds

Oct 18, 2012

More MNKD Zacks Commentary

Financials

EPS TTM	-0.83
Sales	0
Net Income	-172
Price/Earnings	NA
Price/Book	NA
Price/Cash Flow	NA
Price/Sales	NA

More MNKD Financials

News

2 Biotech Approval Outcomes That Might Affect You - TheMotleyFool

Jun 19, 2013

Afternoon Market Gainers - Benzinga

Jun 19, 2013

Insider Trading Investment for MannKind, Intel, Oracle, Nokia, Ford Motor, and Sirius XM Radio - Pr Newswire

Jun 19, 2013

Market Maker Surveillance Report. DVAX, BSX, MNKD, ALU, AGNC, NEWL, Highest Net Sell Volume and Negative Price Friction For Tuesday, June 18th 2013 - M2

Jun 19, 2013

Market Wrap for Wednesday, June 19: Stocks Plunge as Federal Reserve Discusses Pulling Back Stimulus - Benzinga

Jun 19, 2013

Shares of MannKind Receive a Boost, Up 7.0% - Financial News Network Online - Market Movers

Jun 19, 2013

Wednesday's ETF with Unusual Volume: IWC - Marketnewsvideo.Com

Jun 19, 2013

Advanced Treatment Methods, Significant Study Results, Conferences, and Final Study Data Releases - Research Report on Amgen, Celgene, Vertex Pharmaceuticals, MannKind, and Peregrine Pharmaceuticals - Pr Newswire

Jun 18, 2013

See All News Stories on MNKD

Broker Recommendations

Current ABR	2.00
ABR (Last Week)	2.00
# of recs in ABR	6
Average Target Price	7.20
Industry Rank by ABR	112 out of 265
Rank in Industry	29 out of 154

More MNKD Broker Recommendations

Day Low - High	6.65 - 7.25
52wk Low - High	1.79 - 8.06
Previous Close	6.61
Avg. Volume	11,511,901
Industry	MED-BIOMED/GENE
Market Cap	1.92 B
Div - Yield	0.00 - 0.00
Beta	1.32
P/E (F1)	0.00
Current Year Est.	-0.49
Quarterly Earnings ESP	NA

P/E (F1)	NA
PEG Ratio	NA
Current Year Est.	-0.49
Current Quarter Estimate	-0.15
Most Accurate Estimate	NA
Earnings ESP	NA
Next Earnings Report Date	08-06-2013
EPS Last Year	-0.83
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Mannkind Cp: (NASD: MNKD)

$7.02

0.42 (6.28%)

Volume 11,076,972

Jun 19 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-BIOMED/GENE

Zacks Commentary

Financials

News

Broker Recommendations